How Different Genotypes Affect Tacrolimus Levels in Liver Transplant Patients
Author Information
Author(s): Wang Jing, Huang Siqi, Li Yuanchen, Fang Qiu, Wang Min, Zhu Huaijun
Primary Institution: Nanjing Drum Tower Hospital
Hypothesis
The study aims to assess the retention of indoxyl sulfate and hippuric acid in the plasma of liver transplantation subjects carrying different genotypes of ABCB1 and ABCC2.
Conclusion
ABCC2 may be one of the pathways by which tacrolimus pharmacokinetics is altered by indoxyl sulfate.
Supporting Evidence
- Carriers of the rs717620-24T variant exhibited high plasma indoxyl sulfate retention in patients with normal renal function.
- Chronic kidney disease patients and patients with normal renal function exhibited indoxyl sulfate and tacrolimus in the ABCC2 normal function and reduced function groups.
- The study found a strong correlation between plasma indoxyl sulfate level and tacrolimus dose-corrected trough concentration.
Takeaway
This study looked at how different genes in liver transplant patients affect the levels of certain toxins and a medication called tacrolimus.
Methodology
The study included liver transplant patients treated with tacrolimus and analyzed their plasma concentrations of indoxyl sulfate and hippuric acid based on their genotypes.
Potential Biases
The study was conducted at a single center, which may limit the generalizability of the findings.
Limitations
The study only determined the genotypes of liver transplant recipients and lacked information on the genotypes of donors.
Participant Demographics
Most participants were Han Chinese from Jiangsu and Anhui provinces, with a median age of 55 years and 62.9% being men.
Statistical Information
P-Value
0.020
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website